Abstract
PurposeThe CyberKnife® (CK) Synchrony® Xsight® Lung Tracking System (XLTS) ‎enables non-invasive soft tissue-based respiratory tracking as an alternative to fiducial implantation for lung ‎stereotactic body radiotherapy (SBRT). Patient selection has relied on clinician ‎judgment, often resulting in unsuccessful simulations and ‎treatment delays. This study evaluated fiducial-free CK simulation outcomes, identified predictors of successful 2-View tracking, and developed evidence-based patient selection framework.Methods and materialsThirty consecutive patients undergoing fiducial-free CK ‎simulation between April 2022 and March 2024 were ‎retrospectively analysed. Simulation outcomes were classified as 2-View, 1-View, or 0-View based ‎on live X-ray image correlation. Tumour location, diameter, volume, ‎‎density (Hounsfield units), X-ray technique, and axial position ‎were assessed for association ‎with successful 2-View tracking.ResultsSuccessful 2-View tracking was achieved in 33.3% of simulations, while 23.4% and 43.3% resulted in 1-View and 0-View outcomes, respectively. Simulation failure was more frequent in tumours <15 mm, centrally located lesions, or those adjacent to the diaphragm. Successful 2-View tracking was associated with larger tumour volume (mean 4.7 vs 1.6 cm3, p = 0.028) and higher maximum tumour density (67.5 vs 56.0 HU, p = 0.029).ConclusionsThis study evaluated fiducial-free CK simulation to support more consistent patient selection for ‎lung SBRT. Tumour location, diameter, and density may help predict tracking success and reduce unsuccessful simulations. These findings provide a practical framework to guide fiducial use and lay the groundwork for future predictive models to identify, at an early stage, patients likely to require fiducial implantation at biopsy.